This is a working overview of Dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Taco Bell began experimenting with fast-casual and urban concepts when it created U.S. Taco Co. and Urban Taproom in 2014 reflecting a market shift due to the popularity of Chipotle Mexican Grill. The menu consisted of tacos with American fillings, and did not sell the food sold in Taco Bell restaurants, such as burritos. It was launched in Huntington Beach, California, in August 2014. U.S. Taco Co. closed on September 15, 2015, so the company could focus on its new similar Taco Bell Cantina concept, which featured special menu items and served alcohol. It opened its first location a few days later in Chicago's Wicker Park neighborhood, followed by a location in San Francisco about a month later, located less than a block away from AT&T Park. In 2016, Taco Bell launched the Taco Bell Cantina flagship store located on the Las Vegas Strip. The 24-hour restaurant serves alcohol, unique menu items, and features a DJ. It was announced in August 2017 that the store would begin hosting weddings. Taco Bell Cantina currently has locations in San Francisco, Berkeley, Chicago (2 locations), Las Vegas, Austin, Fayetteville, Cincinnati, Cleveland, Atlanta, Newport Beach, San Diego, San Jose, Sacramento, Nashville, with them once having plans to open soon in Somerville, Massachusetts, but as of 2025, there are instead Taco Bell Cantinas in Brookline and Allston, Massachusetts. In March 2020, Taco Bell announced that it would be converting 3 of its suburban stores into Cantinas that year as part of a test run.
Milan Mrksich (born 15 August 1968) is an American chemist. He is the Henry Wade Rogers Professor at Northwestern University with appointments in chemistry, biomedical engineering and cell & developmental biology. He also served as both the founding director of the Center for Synthetic Biology and as an associate director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern. Mrksich also served as the Vice President for Research of Northwestern University. His research involves the chemistry and synthesis of surfaces that contact biological environments. His laboratory has pioneered several technologies, including strategies to integrate living cells with microelectronic devices, methods to enable high throughput assays for drug discovery, and approaches to making synthetic fusion proteins for applications as therapeutics. Most notably, he developed the SAMDI-MS biochip technology that allows for high-throughput quantification of surface-based biochemical assays using MALDI mass spectrometry. Through SAMDI-MS, Mrksich has become a leader in using label-free technology for drug discovery, founding the company SAMDI Tech in 2011 that primarily serves global pharmaceutical companies. His work has been described in over 240 publications (h-index 98), 500 invited talks, and 18 patents.
=== Response from political organizations === Health Care Without Harm opposes the use of recombinant bovine growth hormone due to its adverse impacts on animals and potential harm to humans. Oregon Physicians for Social Responsibility recommends buying products from cows not injected with recombinant bovine growth hormone (rBGH or rBST).
== Discovery and general principles == FFF was devised and first published by J. Calvin Giddings in 1966 and in 1976. Giddings had published many articles on flow-FFF which is the most important FFF technique today. Giddings, credited for the invention of FFF, was professor of chemistry and specialist of chromatography and separation techniques at the University of Utah.
Glial cells are the supporting cells of the neurons. The three types of glial cells are astrocytes, oligodendrocytes, and ependymal cells, known collectively as macroglia, and the smaller scavenger cells known as microglia. Glial stem cells are found in all parts of the adult brain. Glial cells greatly outnumber neurons and apart from their supporting role to neurons, glia – astrocytes in particular have been acknowledged as being able to communicate with neurons involving a signalling process similar to neurotransmission called gliotransmission. They cannot produce an action potential as generated by a neuron but in their large numbers they can produce chemicals expressing excitability that exert an influence on neural circuitry. The star-like shape of the astrocyte allows contact with a great many synapses. Microglia account for about around 5–10% of cells found within the brain.
Sources: en.wikipedia.org
== History == The word "cachexia" is derived from the Greek words kakos 'bad' and hexis 'condition'. English ophthalmologist John Zachariah Laurence was the first to use the phrase "cancerous cachexia", doing so in 1858. He applied the phrase to the chronic wasting associated with malignancy. It was not until 2011 that the term "cancer-associated cachexia" was given a formal definition, with a publication by Kenneth Fearon. Fearon defined it as "a multifactorial syndrome characterized by ongoing loss of skeletal muscle (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment".
A member of the People's Assembly (Arabic: عضو مجلس الشعب) refers to members of the Parliament of Syria. Historically, members of the Syrian parliament have been referred to in Arabic as nā'ib (نائب, "deputy"), plural nuwāb (نواب), a usage rooted in the legislature's earlier incarnation as the Chamber of Deputies (1932–1963). Following the parliament's reconstitution as the People's Assembly under Ba'athist rule in 1971, members came to be more commonly styled "member of the People's Assembly" in official and state-media usage. Nonetheless, "deputy" has persisted as a recognised designation, including in coverage of the current transitional-era Assembly formed after 2024.
Thin reticular fibers (reticulin) of reticular connective tissue form a supporting meshwork inside the node. These reticular cells also form a conduit network within the lymph node that functions as a molecular sieve, to prevent pathogens that enter the lymph node through afferent vessels re-enter the blood stream. The lymph node capsule is composed of dense irregular connective tissue with some plain collagenous fibers, and a number of membranous processes or trabeculae extend from its internal surface. The trabeculae pass inward, radiating toward the center of the node, for about one-third or one-fourth of the space between the circumference and the center of the node. In some animals they are sufficiently well-marked to divide the peripheral or cortical portion of the node into a number of compartments (nodules), but in humans this arrangement is not obvious. The larger trabeculae springing from the capsule break up into finer bands, and these interlace to form a mesh-work in the central or medullary portion of the node. These trabecular spaces formed by the interlacing trabeculae contain the proper lymph node substance or lymphoid tissue. The node pulp does not, however, completely fill the spaces, but leaves between its outer margin and the enclosing trabeculae a channel or space of uniform width throughout. This is termed the subcapsular sinus (lymph path or lymph sinus). Running across it are a number of finer trabeculae of reticular fibers, mostly covered by ramifying cells.
=== E-liquid === The mixture used in vapor products such as e-cigarettes is called e-liquid. E-liquid formulations vary widely. A typical e-liquid contains propylene glycol and glycerin (95%) with a combination of flavorings, nicotine, and other additives (5%). The flavorings may be natural, artificial, or organic. When e-liquids are heated, by-products such as formaldehyde, acetaldehyde, and acrolein can form, at levels that depend on operating conditions and liquid composition. There are many e-liquid makers and more than 15,000 flavors. The e-liquid usually contains nicotine from tobacco, but some products use non-tobacco nicotine, including synthetic lab-made nicotine. Many e-liquids use nicotine salts made by adding organic acids such as benzoic acid to nicotine, so as to reduce throat irritation. Some e-liquids also contain synthetic cooling agents. Many countries regulate what e-liquids can contain. In the US, there are Food and Drug Administration (FDA) compulsory manufacturing standards and American E-liquid Manufacturing Standards Association (AEMSA) recommended manufacturing standards. European Union standards are published in the EU Tobacco Products Directive.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.